Targeting Lp-PLA2 inhibits profibrotic monocyte-derived macrophages in silicosis through restoring
Shifeng Li1, Hong Xu2, Shupeng Liu3
1National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
Abstract:
Monocyte-derived macrophages (MoMacs) are the most important effector cells that cause pulmonary fibrosis. However, the characteristics of MoMac differentiation in silicosis and the mechanisms by which MoMacs affect the progression of pulmonary fibrosis remain unclear. Integration of single-cell and spatial transcriptomic analyses revealed that the silicosis niche was occupied by a subset of MoMacs, identified as Spp1hiMacs, which remain in an immature transitional state of differentiation during silicosis. This study investigated the mechanistic foundations of mitochondrial damage induced by the lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by Pla2g7)-acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1)-cardiolipin (CL) signaling pathway, which interferes with Spp1hiMac differentiation. We demonstrated that in SiO2-induced MoMacs, Lp-PLA2 induces abnormal CL acylation through the activation of ALCAT1, resulting in impaired mitochondrial localization of PINK1 and LC3B and mitochondrial autophagy defects. Simultaneously, lysosomal dysfunction causes the release of the lysosomal protein cathepsin B into the cytoplasm, which involves M1 and M2 macrophage polarization and the activation of proinflammatory and profibrotic pathways. Furthermore, we assessed the efficacy of the Lp-PLA2 inhibitor darapladib in ameliorating silica-induced pulmonary fibrosis in a murine model. Our findings enhance our understanding of silicosis pathogenesis and offer promising opportunities for developing targeted therapies to mitigate fibrotic progression and maintain lung function in affected individuals.
Insights
Monocyte-derived macrophages (MoMacs) drive pulmonary fibrosis. This study reveals immature Spp1hiMacs in silicosis, linking mitochondrial damage via Lp-PLA2 to impaired differentiation and fibrosis progression.
Area of Science:
- Pulmonary fibrosis research
- Macrophage biology
- Silicosis pathogenesis
Background:
- Monocyte-derived macrophages (MoMacs) are key in pulmonary fibrosis.
- MoMac differentiation and mechanisms in silicosis are not fully understood.
Purpose of the Study:
- To characterize MoMac differentiation in silicosis.
- To elucidate mechanisms of MoMac-driven fibrosis.
- To evaluate Lp-PLA2 inhibition for silicosis therapy.
Main Methods:
- Integrated single-cell and spatial transcriptomics.
- Analysis of the Lp-PLA2-ALCAT1-CL signaling pathway.
- In vivo murine model of silica-induced pulmonary fibrosis.
Main Results:
- Identified Spp1hiMacs as immature MoMacs in silicosis.
- Demonstrated Lp-PLA2-induced mitochondrial and lysosomal dysfunction.
- Showed darapladib ameliorates silica-induced pulmonary fibrosis in mice.
Conclusions:
- Silicosis involves impaired MoMac differentiation via mitochondrial damage.
- The Lp-PLA2 pathway is a critical mediator of fibrosis.
- Lp-PLA2 inhibition offers a potential therapeutic strategy for silicosis.


